Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Conditions:   Breast Cancer;   Metastatic Breast Cancer;   Hormone Receptor-positive Breast Cancer;   HER2-negative Breast Cancer
Interventions:   Drug: Fulvestrant;   Drug: Anastrozole;   Drug: Abemaciclib
Sponsor:   University of California, Irvine
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 3, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments